Oragenics, Inc. (NYSEMKT:OGEN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. |
(a) The 2017 annual meeting of shareholders of Oragenics, Inc.
was held on May4, 2017.
(b) At the 2017 annual meeting, the following proposals were
voted on by our shareholders:
PROPOSAL I:Election of Directors.
Dr.Frederick Telling, Dr.Alan Joslyn, Mr.Robert Koski, Mr.Charles
Pope, and Dr.Alan Dunton were each re-elected as Directors, to
serve until our next annual meeting of shareholders or until
their respective successors are elected and qualified or until
their earlier resignation, removal from office or death. The
votes were as follows:
| For | Withheld | BrokerNon- Votes | ||||||||||
|
Dr.Frederick Telling |
36,941,052 | 593,941 | 6,852,905 | |||||||||
|
Dr.Alan Joslyn |
37,106,293 | 428,700 | 6,852,905 | |||||||||
|
Robert Koski |
37,105,973 | 429,020 | 6,852,905 | |||||||||
|
Charles Pope |
37,026,892 | 508,101 | 6,852,905 | |||||||||
|
Dr.Alan Dunton |
34,986,746 | 2,548,247 | 6,852,905 |
PROPOSAL
II: To conduct a non-binding advisory vote on executive
compensation. The votes were as follows:
|
FOR |
37,143,404 | |||
|
AGAINST |
345,510 | |||
|
ABSTAIN |
46,079 | |||
|
BROKER NON-VOTES |
6,852,905 |
PROPOSAL
III: Ratification of the selection of Mayer Hoffman
McCann P.C. as the Companys independent auditors for the year
ending December31, 2017.
|
FOR |
44,276,851 | |||
|
AGAINST |
47,882 | |||
|
ABSTAIN |
63,165 |
PROPOSAL
IV: Approval of an amendment to the Companys 2012 Equity
Incentive Plan.
|
FOR |
37,122,615 | |||
|
AGAINST |
365,088 | |||
|
ABSTAIN |
47,290 | |||
|
BROKER NON-VOTES |
6,852,905 |
Item9.01
FINANCIAL STATEMENTS AND EXHIBITS.
| (d) | Exhibits |
| Exhibit No. | Description | |
| 4.1 | 2012 Equity Incentive Plan.* | |
| 4.2 | First Amendment to 2012 Equity Incentive Plan. |
| * |
Document has been previously filed with the Commission as Exhibit 4.1 to Form 8-K filed on October25, 2012 and is incorporated by reference. |
About Oragenics, Inc. (NYSEMKT:OGEN)
Oragenics, Inc. develops, markets and sells probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora. The Company is focused on offering antibiotics against infectious disease and on developing treatments for oral mucositis. It is engaged in developing its antibiotic product candidate, MU1140, as well as other homolog antibiotic product candidates; researching AG013 in connection with the treatment of Oral Mucositis; commercializing its ProBiora3 probiotic products, and has other product candidates for out licensing or partnering. MU1140 is an antibiotic that is produced by the parent of the SMaRT strain. ProBiora3 is a blend of three naturally occurring strains of beneficial bacteria, including Streptococcus oralis KJ3, Streptococcus uberis KJ2 and Streptococcus rattus JH145. LPT3-04 is a compound, which is consumed in the human diet in small amounts and results in dose-dependent weight loss in experimental animal models. Oragenics, Inc. (NYSEMKT:OGEN) Recent Trading Information
Oragenics, Inc. (NYSEMKT:OGEN) closed its last trading session down -0.040 at 0.400 with 11,283 shares trading hands.